Published in Vaccine Weekly, August 11th, 2004
Staley will be responsible for overseeing strategic planning and technology assessment to guide the implementation of information technology infrastructure necessary to support the commercialization of Provenge, Dendreon's therapeutic cancer vaccine currently in phase III clinical trials for prostate cancer, and other products.
Staley spent the last 13 years at Cardinal Health, Inc.'s, nuclear pharmacy division where she was most recently executive director, pharmacy services liaison, information technologies. At Cardinal Health, Staley...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2004-08-11)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.